News | February 23, 2022
Vicore advances on new chemical entity from VP03 program
Four additional AT2R agonists are expected to finalize preclinical evaluation during 2022
Four additional AT2R agonists are expected to finalize preclinical evaluation during 2022
The partnership includes multiple collaboration areas and is an important milestone for bringing cost-competitive biobased products to the market, with applications in the pharmaceutical, agricultural, cosmetics and personal care, and automotive industries
IOL Chemicals and Pharmaceuticals has reported standalone financial results for the period ended December 31, 2021
It will be marketed under the brand name Molunamax
J. B. Chemicals & Pharmaceuticals Limited (JBCPL), announced its financial results for the second quarter ended 30th September, 2021
'Unit-9' for manufacturing Gabapentin & other pharma (APIs) products is expected to be complete in Q3FY22
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
The company recorded revenue of Rs 528crore as compared to Rs 444 crore, registering a growth of 19% over the corresponding quarter ended 31st March 2020
The company received approval for 2-Methyl-5Nitro-Imidazole (2-MNI) with a committed production capacity of 4,000 MT per annum.
The company posted net profit of Rs.62.17 crores for the period ended December 31, 2019.
Subscribe To Our Newsletter & Stay Updated
